Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.36 |
| ▸ | CDK9 | P50750 | 8/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287250 | 1.00 | CCNT1 (0.36) | CCNT1CDK9SLC9A1HRH1HTR6 | |
| SCHEMBL8133510 | 0.87 | CYP1A2 (0.36) | CCNT1CDK9SLC9A1CHRM5CHRM1 | |
| SCHEMBL5095974 | 0.80 | CCNT1 (0.39) | CCNT1CDK9SCN9AMKNK1LRRK2 | |
| SCHEMBL4356507 | 0.77 | CCNT1 (0.41) | CCNT1CDK9HRH1HTR6SCN9A | |
| SCHEMBL14287249 | 0.76 | CYP2C9 (0.38) | HTR6GAACYP1A2CYP2C9 | |
| SCHEMBL13667591 | 0.75 | CCNT1 (0.38) | CCNT1CDK9CHRM5CHRM1 | |
| SCHEMBL8111928 | 0.74 | CCNT1 (0.36) | CCNT1CDK9CHRM5CHRM1SCN9A | |
| SCHEMBL3013040 | 0.74 | CCNT1 (0.36) | CCNT1CDK9CHRM5CHRM1SCN9A | |
| SCHEMBL8119153 | 0.74 | CCNT1 (0.36) | CCNT1CDK9SCN9AMKNK1LRRK2 | |
| SCHEMBL3024239 | 0.74 | CCNT1 (0.36) | CCNT1CDK9CHRM5CHRM1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CCNT1 4868/4885CDK9 4231/4885SLC9A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.